TheSUBWAY.com Announces Investment Opinion on Rascals International Inc., US Onocology Inc., Micro Strategy Inc., Talk.com and Repligen Corp.Business Editors NOTE TO EDITORS: The following is an investment opinion issued by TheSUBWAY.com. WESTON, Fla.--(BUSINESS WIRE)--March 28, 2001 Rascals International Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :RASC RASC Royal Astronomical Society of Canada RASC Reconfigurable Application Specific Computing RASC Royal Army Service Corps (British) RASC Royal Agricultural Society of the Commonwealth (UK) ) Previous Close Up 66% to .25 on volume 50,000 Shares: ATTRACTIVE RASC is new to TheSUBWAY.com, and CRG CRG Centre for Research on Globalisation CRG Council for Responsible Genetics CRG Contingency Response Group CRG Citizens for Responsible Government CRG Corporate Renaissance Group CRG Columbia River Gorge CRG Consulting Resource Group CRG Columbia Resource Group is expecting good things from the company. CRG expects to see the stock trading over the $3.00 mark in the short term. Watch for some interesting things to come in RASC. Rascals International owns comedy clubs in Ocean Township, New Jersey Ocean Township is the name of some places in the U.S. state of New Jersey:
US Oncology, Inc. (Nasdaq:USON) Previous Close: Dn 15% to $7.688 on vol. 1,868,400 Shares: HOLD US Oncology recently announced results for the fourth quarter and twelve months ended December 31, 2000. Revenues for the fourth quarter increased 19% to $355.8 million from $299.5 million reported in the comparable quarter last year. Net income, excluding one-time charges, increased to $11.9 million, or $.12 per share, in the fourth quarter 2000 compared to $10.2 million, or $.10 per share, during the same period in 1999, an increase of 20%. Net loss, including one-time charges, was $123.3 million, or $(1.25) per share, compared to net income of $17.9 million, or $0.18 per share, in fourth quarter of 1999. During the quarter, US Oncology recorded $209 million in one-time charges, of which $201 million was non-cash, related to impairment of assets, restructuring of operations, additional bad-debt expense and cashless exercise of options. 'As we look to the future, we do so with a focused management team, significant opportunities to leverage the network, revalued assets, a reduced cost structure, and a strong balance sheet and cash flow,' CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Ross said. 'Equally important, we have a stable network, comprised of over 495 sites, 72 cancer centers and over 850 physicians, representing approximately 15% of the U.S. cancer market, that supports the focused strategic direction of the Company.' US Oncology's network of affiliated practices is the largest provider of integrated cancer care in the United States. MicroStrategy Inc. (Nasdaq:MSTR MSTR Microstrategy, Inc (stock symbol) MSTR Master MSTR Minneapolis and St. Louis (railroad) MSTR Master Mode ) Previous Close: Down 4% to $3.813 on vol. 732,700 Shares: ACCUMULATE MicroStrategy, a leading worldwide provider of business intelligence software, announced it has strengthened its relationship with IBM (International Business Machines Corporation, Armonk, NY, www.ibm.com) The world's largest computer company. IBM's product lines include the S/390 mainframes (zSeries), AS/400 midrange business systems (iSeries), RS/6000 workstations and servers (pSeries), Intel-based servers (xSeries) through the launch of MicroStrategy SDK (Software Developer's Kit) See developer's toolkit and Windows SDK. SDK - Software Developers Kit (or "Software Development Kit"). 7.1 Java edition. MicroStrategy SDK, MicroStrategy's comprehensive development environment for the MicroStrategy 7 web reporting and business intelligence platform, is designed to seamlessly integrate with IBM WebSphere* Application Server, IBM's e-business application deployment environment built on open-standards based technology. 'IBM's WebSphere Application Server provides the highly scalable and reliable foundation for MicroStrategy's SDK solution,' said Paraic Sweeney, vice president of marketing, WebSphere software platform, IBM. 'This relationship will provide businesses with the power of the WebSphere software for e-business and MicroStrategy's SDK solution for building business intelligence applications.' MicroStrategy 7, the company's business intelligence platform, is an easy to use, easy to deploy departmental and enterprise reporting product that will answer a vast array of business questions. MicroStrategy is a leading worldwide provider of business intelligence software and related services. MicroStrategy's technology platform enables companies to build solutions that provide powerful insight into business operations and create lasting, profitable relationships with partners, supply- chains, and customers. MicroStrategy delivers these solutions via web, wireless, and voice. MicroStrategy also offers a comprehensive set of consulting, training and support services support services Psychology Non-health care-related ancillary services–eg, transportation, financial aid, support groups, homemaker services, respite services, and other services for its customers and partners. TALK.com (Nasdaq:TALK) Previous Close: Up 30% to $1.75 on vol. 750,900 Shares: ATTRACTIVE TALK.com, an integrated communications provider that offers all-in-one telecom services, will provide California residents with fixed price packages of local and long distance telephone service including unlimited features such as call waiting and voice mail. California marks the 13th state where TALK.com offers local and long distance to residents and small businesses, complementing millions who already use TALK's established nationwide long distance network. Now, Pacific Bell customers can enjoy real choice in comprehensive phone service, with quality that surpasses the typical 'Bell experience'. 'We are confident that servicing the huge and fast growing market niche of consumers is a tremendous business opportunity. We are on track to address 70% of the market with approximately 28 states by year end,' stated Chairman and CEO of TALK.com Gabe Battista. 'Consumers want the simplicity and value of local and long distance from one provider. We answer that need by providing the same quality of call with more features for a better price.' Including California's 17.5 million access lines, TALK's current number of addressable lines totals over 70 million - part of an enormous market, exceeding 120 million lines available to service TALK.com customers. Repligen Corp. (Nasdaq:RGEN) Previous Close: Up 29% to $3.00 on vol. 658,700 Shares: ATTRACTIVE Repligen recently announced plans for a Phase 2 trial of uridine uridine /uri·dine/ (ur´i-den) a pyrimidine nucleoside containing uracil and ribose; it is a component of nucleic acid and its nucleosides are involved in the biosynthesis of polysaccharides. Symbol U. therapy in a subset of mitochondrial disease mitochondrial disease Any clinically heterogeneous multisystem disease characterized by defects of brain–mitochondrial encephalopathies and/or muscle–mitochondrial myopathies due to alterations in the protein complexes of the electron transport chain of patients based on Phase 1 data obtained by investigators at the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. (UCSD UCSD University of California, San Diego (La Jolla, California) UCSD User Centered System Design UCSD Urbana-Champaign Sanitary District (Illinois) UCSD Ultra Cool Sexy Dudes ). The Phase 1 clinical trial phase 1 clinical trial Phase 1 study. See Phase study. results were presented at 'Mitochondria 2001', a joint meeting of the Mitochondrial mitochondrial pertaining to mitochondria. mitochondrial RNAs a unique set of tRNAs, mRNAs, rRNAs, transcribed from mitochondrial DNA by a mitochondrial-specific RNA polymerase, that account for about 4% of the total cell RNA that Medicine Society and the Mitochondrial Research Society held in San Diego. The Phase 1 results indicate that therapy with uridine, or a prodrug of uridine (triacetyl uridine, 'TAU') was well tolerated in children with severe to moderate disease. In addition, several patients were observed to have improvements in one or more of their major symptoms, including reduction in the number of neurologic setbacks with infection, reduced frequency of seizures and improvements in growth, development, coordination or strength. The Phase 2 trial will be a double-blind, placebo-controlled, randomized clinical trial randomized clinical trial, n a clinical study where volunteer participants with comparable characteristics are randomly assigned to different test groups to compare the efficacy of therapies. evaluating the potential of TAU to correct kidney disease Kidney Disease Definition Kidney disease is a general term for any damage that reduces the functioning of the kidney. Kidney disease is also called renal disease. in patients with mitochondrial disease and renal tubular acidosis Renal Tubular Acidosis Definition Renal tubular acidosis (RTA) is a condition characterized by too much acid in the body due to a defect in kidney function. Description Chemical balance is critical to the body's functioning. . Repligen Corporation develops new drugs for debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. disorders including autism autism (ô`tĭzəm), developmental disability resulting from a neurological disorder that affects the normal functioning of the brain. It is characterized by the abnormal development of communication skills, social skills, and reasoning. , cancer, and immune and metabolic disorders. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to produce therapeutic antibodies. "Tuesday's action in the stock market marked a shift in investor sentiment, away from one that favors bleak economic news that could foster more interest rate reductions, to one that appreciates affirmative economic data that could signal economic recovery. This kind of shift should be considered healthy for the financial markets, as it transfers investors' focus away from the Federal Reserve, and realigns it more closely with stock market fundamentals." Stated Peter Antipatis. More is available at: http://www.TheSUBWAY.com. About TheSubway.com TheSubway.com, a wholly owned online asset of Capital Research Group, Inc. (CRG) was developed solely for experienced, risk tolerant investors. Subscribers to TheSubway.com receive daily market commentary reports for select companies trading on various markets. Sophisticated investors are also able to receive for free, select, rare research reports and investor kits on up and coming emerging companies while they are still not widely known. About Capital Research Group Inc. Through TheSubway.com, Capital Research Group (CRG) introduces what in its opinion are undervalued companies to the investment community. Capital Research Group strives to locate companies with enormous growth potential. CRG is a full service public relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most / Investor relations Investor relations The process by which the corporation communicates with its investors. firm. For more information about our products or services, please contact CRG at 954-217-9555 or visit us at http://www.thesubway.com. All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market marker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on www.thesubway.com. CRG has not yet been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. (400,000 RASC is pending) CRG intends to sell its shares. CRG has sold approximately 0 RASC shares to date. CRG may sell its shares for less than the target price given in this opinion. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion